Numbers first: 96.4% · orforglipron · QYB.
This is a planning question. I know what my options are; I do not know how to weigh them.
What I want is the minimum viable version, which I suspect is smaller than what I would design.
What is the minimum version of this that is still defensible?
Specifically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
If you are ranking vendors, specify a method and have all samples tested at the same place.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAsk PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.